See more : DeepMatter Group Plc (DMTR.L) Income Statement Analysis – Financial Results
Complete financial analysis of ZIOPHARM Oncology, Inc. (ZIOP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ZIOPHARM Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- CSB Bank Limited (CSBBANK.NS) Income Statement Analysis – Financial Results
- Toa Road Corporation (1882.T) Income Statement Analysis – Financial Results
- Alice Queen Limited (AQX.AX) Income Statement Analysis – Financial Results
- Patriot National Bancorp, Inc. (PNBK) Income Statement Analysis – Financial Results
- Eik fasteignafélag hf. (EIK.IC) Income Statement Analysis – Financial Results
ZIOPHARM Oncology, Inc. (ZIOP)
About ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 146.00K | 6.39M | 6.86M | 4.33M | 1.37M | 800.00K | 800.00K | 667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57K | 1.73K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 146.00K | 6.39M | 6.86M | 4.33M | 1.37M | 800.00K | 800.00K | 667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57K | 1.73K |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 52.70M | 38.33M | 34.13M | 45.08M | 157.79M | 106.79M | 32.71M | 42.85M | 83.45M | 57.08M | 12.91M | 4.56M | 17.25M | 18.99M | 10.39M | 5.59M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 27.67M | 19.53M | 19.92M | 14.80M | 14.38M | 17.65M | 12.17M | 15.66M | 19.52M | 14.98M | 11.64M | 7.57M | 8.37M | 9.58M | 8.72M | 4.19M | 39.17K | 35.36K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 120.00 |
| SG&A | 27.67M | 19.53M | 19.92M | 14.80M | 14.38M | 17.65M | 12.17M | 15.66M | 19.52M | 14.98M | 11.64M | 7.57M | 8.37M | 9.58M | 8.72M | 4.19M | 39.17K | 35.36K | 0.00 | 120.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 486.00 | -42.51K | 74.14K |
| Operating Expenses | 80.36M | 57.86M | 54.05M | 59.88M | 172.17M | 124.43M | 44.87M | 58.51M | 102.97M | 72.07M | 24.55M | 12.12M | 25.62M | 28.57M | 19.11M | 9.79M | 39.17K | 35.84K | -42.51K | 74.26K |
| Cost & Expenses | 80.36M | 57.86M | 54.05M | 59.88M | 172.17M | 124.43M | 44.87M | 58.51M | 102.97M | 72.07M | 24.55M | 12.12M | 25.62M | 28.57M | 19.11M | 9.79M | 39.17K | 35.84K | 42.51K | 74.26K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 388.00K | 1.96M | 1.25M | 270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.13M | 629.00K | 575.00K | 369.00K | 290.00K | 357.00K | 462.00K | 738.00K | 658.00K | 268.00K | 188.00K | 330.00K | 388.00K | 433.35K | 173.92K | 101.23K | 0.00 | 486.00 | 799.00 | 750.00 |
| EBITDA | -78.85M | -117.17M | -52.54M | -53.95M | -165.01M | -119.73M | -31.32M | -56.37M | -95.47M | -63.51M | -32.48M | -7.32M | -24.84M | -26.17M | -17.68M | -9.42M | -39.17K | -35.36K | -39.14K | -71.79K |
| EBITDA Ratio | 0.00% | 0.00% | -35,987.67% | -844.48% | -2,405.00% | -2,763.87% | -2,281.06% | -7,046.13% | -11,934.25% | -9,521.74% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,523.04% | -4,159.04% |
| Operating Income | -79.98M | -117.80M | -53.12M | -54.32M | -165.30M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | -26.61M | -17.86M | -9.52M | -39.17K | -35.84K | -39.94K | -72.54K |
| Operating Income Ratio | 0.00% | 0.00% | -36,381.51% | -850.26% | -2,409.23% | -2,772.11% | -2,314.71% | -7,138.38% | -12,016.50% | -9,561.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| Total Other Income/Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.62M | -8.12M | 4.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -79.98M | -117.80M | -53.12M | -54.32M | -165.30M | -120.09M | -31.78M | -57.11M | -96.13M | -56.16M | -40.79M | -3.18M | 0.00 | 0.00 | 0.00 | 0.00 | -39.17K | -35.84K | -39.94K | -72.54K |
| Income Before Tax Ratio | 0.00% | 0.00% | -36,381.51% | -850.26% | -2,409.23% | -2,772.11% | -2,314.71% | -7,138.38% | -12,016.50% | -8,419.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.62M | -8.12M | 4.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -79.98M | -117.80M | -53.12M | -54.32M | -165.30M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | -26.61M | -17.86M | -9.52M | -39.17K | -35.84K | -39.94K | -72.54K |
| Net Income Ratio | 0.00% | 0.00% | -36,381.51% | -850.26% | -2,409.23% | -2,772.11% | -2,314.71% | -7,138.38% | -12,016.50% | -9,561.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| EPS | -0.38 | -0.70 | -0.37 | -0.40 | -1.27 | -0.96 | -0.31 | -0.66 | -1.22 | -0.97 | -0.71 | -0.33 | -1.19 | -1.41 | -1.42 | -2.32 | -0.29 | -0.31 | -0.36 | -0.80 |
| EPS Diluted | -0.38 | -0.70 | -0.37 | -0.40 | -1.27 | -0.96 | -0.31 | -0.66 | -1.22 | -0.97 | -0.71 | -0.33 | -1.19 | -1.41 | -1.42 | -2.32 | -0.29 | -0.31 | -0.36 | -0.80 |
| Weighted Avg Shares Out | 209.64M | 167.95M | 143.71M | 136.94M | 130.39M | 125.42M | 101.13M | 85.94M | 78.55M | 66.00M | 46.00M | 23.11M | 21.23M | 18.83M | 12.57M | 4.10M | 135.99K | 116.82K | 112.49K | 90.27K |
| Weighted Avg Shares Out (Dil) | 209.64M | 167.95M | 143.71M | 136.94M | 130.39M | 125.42M | 101.13M | 85.94M | 78.55M | 66.00M | 46.00M | 23.11M | 21.23M | 18.83M | 12.57M | 4.10M | 135.99K | 116.82K | 112.49K | 90.27K |
Why Shares of Ziopharm Oncology Jumped on Wednesday
Ziopharm Oncology to Participate in September Investor Conferences
Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions
ZIOPHARM Oncology's (ZIOP) CEO Heidi Hagen on Q2 2021 Results - Earnings Call Transcript
Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021
Ziopharm Oncology to Participate in Upcoming Conferences
Ziopharm Oncology Reinforces Clear and Bold Vision for Delivering Value at Annual Shareholders Meeting
ZIOPHARM Oncology, Inc.'s (ZIOP) Interim CEO Heidi Hagen on Q1 2021 Results - Earnings Call Transcript
Ziopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 Annual Meeting
Why Ziopharm Oncology Stock Is Sinking Today
Source: https://incomestatements.info
Category: Stock Reports